title: [PSA and blood test diagnostics of prostate cancer].
abstract: Gleason grading of tumor biopses is the only method to distinguish clinically significant prostate cancer. Local cancer is usually symptomless, and men would benefit from functional screening. The aim of improving blood test diagnostics is to find those for whom it is profitable on the basis of blood test to proceed to biopsies. Overdiagnosis would be simultaneously avoided. In blood test diagnostics, established use is made only of the levels of prostate-specific antigen (PSA) and free PSA. New methods for blood test diagnosis are "Prostate Health Index" and the four-kallikrein panel.
authors.forename: Heikki
authors.initials: H
authors.lastname: Seikkula
authors.forename: Kim
authors.initials: K
authors.lastname: Pettersson
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Boström
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001706:Biopsy; D055088:Early Detection of Cancer; D006403:Hematologic Tests / Q000379:methods*; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D060787:Neoplasm Grading; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D007610:Kallikreins; D017430:Prostate-Specific Antigen